Search

Your search keyword '"Tellez N"' showing total 75 results

Search Constraints

Start Over You searched for: Author "Tellez N" Remove constraint Author: "Tellez N"
75 results on '"Tellez N"'

Search Results

1. OCT Variability Prevents Their Use as Robust Biomarkers in Multiple Sclerosis

2. An experimental setup to generate narrowband bi-photons via four-wave mixing in cold atoms

3. Gauging Biases in Various Deep Learning AI Models

6. An Assure AI Bot (AAAI bot)

7. An experimental setup to generate narrowband bi-photons via four-wave mixing in cold atoms

8. Interferon beta in relapsing--remitting multiple sclerosis; An eight years experience in a specialist multiple sclerosis centre

11. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial

13. Partial trysomy 11q due to a ins(22;11)(q13.3;q14.2q23.3)pat

15. Spanish Registry of patients with multiple sclerosis treated with fingolimod (GILENYA Registry): safety and effectiveness after one year on treatment

16. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

17. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL

18. Health-related quality of life in multiple sclerosis: Effects of natalizumab

19. The incidence and significance of anti-natalizumab antibodies. Results from the AFFIRM and SENTINEL

20. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

23. Cambio de tratamiento en pacientes con esclerosis múltiple y sus consecuencias en la práctica clínica

24. La tomografía computarizada de perfusión permite superar importantes criterios de exclusión SITS-MOST para la trombólisis endovenosa del infarto cerebral

32. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)

33. 40 EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

35. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal

36. Long-term clinical outcome of primary progressive MS:Predictive value of clinical and MRI data

37. The relationship between cannabis and cardiovascular disease: clearing the haze.

39. Production and purification of outer membrane vesicles encapsulating green fluorescent protein from Escherichia coli : a step towards scalable OMV technologies.

40. Addressing Cardiovascular Toxicity Risk of Electronic Nicotine Delivery Systems in the Twenty-First Century: "What Are the Tools Needed for the Job?" and "Do We Have Them?"

41. Effect of resistance exercise training on plasma neurofilaments in multiple sclerosis: a proof of concept for future designs.

42. Correlation Between Demographic Variables and Complications in Nonsyndromic Craniosynostosis.

43. Sevoflurane Exposure in Neonates Perturbs the Expression Patterns of Specific Genes That May Underly the Observed Learning and Memory Deficits.

44. Generation of two iPSC lines from long QT syndrome patients carrying SNTA1 variants.

45. Dexmedetomidine Pre-Treatment of Neonatal Rats Prevents Sevoflurane-Induced Deficits in Learning and Memory in the Adult Animals.

46. Dexmedetomidine does not compromise neuronal viability, synaptic connectivity, learning and memory in a rodent model.

47. A synthetic peptide rescues rat cortical neurons from anesthetic-induced cell death, perturbation of growth and synaptic assembly.

48. SS-31 Peptide Reverses the Mitochondrial Fragmentation Present in Fibroblasts From Patients With DCMA, a Mitochondrial Cardiomyopathy.

49. Cellular models for human cardiomyopathy: What is the best option?

50. Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II).

Catalog

Books, media, physical & digital resources